Top 200 Drugs Study Guide Summary
For the PTCE, focus on each drug’s brand and generic names, therapeutic class, primary indication, and a red‑flag adverse effect/contraindication. Use the suffix cheat sheet and the tables below to study faster and spend more time on the rest of the exam.
Disclaimer: This post is informational only and intended to guide students in studying for the PTCE. It is not meant to represent comprehensive drug information and should not be used as a reference for patient care or decision-making.
On this page
- What the “Top 200 drugs” means for the PTCE
- PTCE exam weight: how many medication questions?
- How to memorize the Top 200 (step-by-step)
- Suffix cheat sheet
- Quick‑study tables by class
- Class‑by‑class overview (uses & gotchas)
- High‑risk side effects & interactions
- Mini self-test
- FAQs
- Resources
- Abbreviations Used in this Guide
What the “Top 200 drugs” means for the PTCE
The Top 200 drugs are the most commonly prescribed outpatient medications in the U.S. There is no single “official” PTCB list. This study convention is drawn from prescribing data and teaching curricula. For the exam, you should be comfortable with each drug’s brand and generic names, class, primary use, and one or two high-yield adverse effects/contraindications. Verify clinical specifics in label sources like DailyMed or FDALabel.
PTCE exam weight: how many medication questions?
Through 2025, the Medications domain is 40% of the PTCE.
Effective January 2026: it becomes 35% with small shifts across other domains. Medications remain the most significant single portion of the exam. See the PTCB content outlines: current guidebook and effective‑Jan‑2026 PDF.
How to memorize the Top 200 (step‑by‑step)
- Group by class. Learn common effects and uses once; apply to all members.
- Learn the suffix patterns. E.g., –pril (ACE inhibitors), –sartan (ARBs), –olol (β‑blockers), –statin (statins).
- Drill brand and generic names daily. Use spaced‑repetition flashcards and mix look-alike/sound-alike pairs.
- Attach one primary use + one red‑flag effect to each drug as you go.
- Spiral review. Re-test older material at increasing intervals; shuffle classes.
Tip: Keep your flashcards in a 3-column format—Brand → Generic → Class—to speed class recognition during the exam.
Suffix cheat sheet
| Suffix | Class | Common examples | Primary use | Red‑flag effect | 
| ‑pril | ACE inhibitors | lisinopril | HTN/HF | cough, hyperkalemia | 
| ‑sartan | ARBs | losartan, valsartan | HTN/HF | hyperkalemia | 
| ‑olol | β‑blockers | metoprolol, atenolol | HTN/angina/HF | bradycardia | 
| ‑dipine | DHP CCBs | amlodipine, nifedipine | HTN | edema | 
| ‑statin | HMG‑CoA reductase inhibitors | atorvastatin, rosuvastatin | hyperlipidemia | myopathy | 
| ‑prazole | PPIs | omeprazole, pantoprazole | GERD | ↓Mg, infection risk (long‑term) | 
| ‑tidine | H2 blockers | famotidine | GERD | confusion (elderly) | 
| ‑gliptin | DPP‑4 inhibitors | sitagliptin | T2DM | nasopharyngitis | 
| ‑gliflozin | SGLT2 inhibitors | empagliflozin | T2DM/HF | genital infections | 
| ‑cillin | Penicillins | amoxicillin | infections | allergy/rash | 
| ‑floxacin | Fluoroquinolones | ciprofloxacin, levofloxacin | infections | tendon rupture | 
| ‑azole | Azole antifungals | fluconazole | fungal infections | hepatotoxicity | 
| ‑zosin | α1‑blockers | tamsulosin | BPH | orthostasis | 
| ‑oxetine / ‑pram | SSRIs | fluoxetine, citalopram | depression/anxiety | sexual dysfunction | 
Quick‑study tables: brand↔generic, class, primary use, key effect
The entries below cover the most frequently tested classes. Use them to build your deck. For complete clinical information, check labels on DailyMed or FDALabel. For macro context, see the University of Arizona’s annual Top 200 posters.
Cardiovascular (hypertension, lipids, heart failure)
| Brand | Generic | Class | Primary use | Key red‑flag | 
| Zestril / Prinivil | lisinopril | ACE inhibitor | HTN/HF | cough, hyperkalemia | 
| Cozaar | losartan | ARB | HTN/HF | hyperkalemia | 
| Diovan | valsartan | ARB | HTN/HF | hyperkalemia | 
| Norvasc | amlodipine | DHP CCB | HTN | edema | 
| Toprol‑XL / Lopressor | metoprolol | β‑blocker | HTN/angina/HF | bradycardia | 
| Tenormin | atenolol | β‑blocker | HTN | bradycardia | 
| Coreg | carvedilol | β‑blocker | HF/HTN | dizziness | 
| Microzide | hydrochlorothiazide | thiazide diuretic | HTN | hypokalemia | 
| Lasix | furosemide | loop diuretic | edema/HF | hypokalemia, ototoxicity | 
| Aldactone | spironolactone | K‑sparing diuretic | HF/HTN | hyperkalemia, gynecomastia | 
| Lipitor | atorvastatin | statin | hyperlipidemia | myopathy | 
| Crestor | rosuvastatin | statin | hyperlipidemia | myopathy | 
| Zocor | simvastatin | statin | hyperlipidemia | myopathy | 
| Plavix | clopidogrel | antiplatelet | ASCVD | bleeding | 
| Eliquis | apixaban | Anticoagulant | AF/VTE | bleeding | 
| Xarelto | rivaroxaban | Anticoagulant | AF/VTE | bleeding | 
| Coumadin | warfarin | Anticoagulant | AF/VTE | bleeding; many interactions | 
Endocrine & metabolic
| Brand | Generic | Class | Primary use | Key red‑flag | 
| Glucophage | metformin | biguanide | Diabetes | GI upset; rare lactic acidosis | 
| Amaryl | glimepiride | sulfonylurea | Diabetes | hypoglycemia | 
| Glucotrol | glipizide | sulfonylurea | Diabetes | hypoglycemia | 
| Jardiance | empagliflozin | SGLT2 inhibitor | Diabetes | genital infections | 
| Ozempic | semaglutide | GLP‑1 RA | Diabetes/weight loss | GI effects (class warning for thyroid C‑cell tumors) | 
| Lantus | insulin glargine | basal insulin | Diabetes | hypoglycemia | 
| Humalog | insulin lispro | rapid insulin | Diabetes | hypoglycemia | 
| Levemir | insulin detemir | basal insulin | Diabetes | hypoglycemia | 
| Synthroid | levothyroxine | thyroid hormone | hypothyroidism | over‑replacement → palpitations | 
| Zyloprim | allopurinol | xanthine oxidase inhibitor | gout | rash (SJS/TEN) | 
| Uloric | febuxostat | xanthine oxidase inhibitor | gout | CV risk warning | 
CNS & psychiatric
| Brand | Generic | Class | Primary use | Key red‑flag | 
| Zoloft | sertraline | SSRI | depression/anxiety | sexual dysfunction | 
| Lexapro | escitalopram | SSRI | depression/anxiety | QT risk at high dose | 
| Prozac | fluoxetine | SSRI | depression | activating/insomnia | 
| Cymbalta | duloxetine | SNRI | depression/neuropathic pain | ↑BP | 
| Effexor XR | venlafaxine | SNRI | depression/anxiety | ↑BP, withdrawal | 
| Elavil | amitriptyline | TCA | neuropathic pain | anticholinergic effects | 
| Wellbutrin SR/XL | bupropion | NDRI | depression/smoking | seizures (dose-related) | 
| Xanax | alprazolam | benzodiazepine | anxiety | sedation, dependence | 
| Ativan | lorazepam | benzodiazepine | anxiety | sedation | 
| Ambien | zolpidem | hypnotic | insomnia | complex sleep behaviors | 
| Seroquel | quetiapine | atypical antipsychotic | schizophrenia | metabolic effects | 
| Risperdal | risperidone | atypical antipsychotic | schizophrenia | hyperprolactinemia | 
| Aricept | donepezil | acetylcholinesterase inhibitor | Alzheimer’s | bradycardia, GI | 
Respiratory & allergy
| Brand | Generic | Class | Primary use | Key red‑flag | 
| ProAir / Proventil / Ventolin | albuterol | SABA | asthma | tachycardia | 
| Advair | fluticasone/salmeterol | ICS/LABA | asthma/COPD | oral thrush (rinse) | 
| Symbicort | budesonide/formoterol | ICS/LABA | asthma/COPD | oral thrush (rinse) | 
| Spiriva | tiotropium | LAMA | COPD | dry mouth | 
| Singulair | montelukast | leukotriene antagonist | asthma/allergy | neuropsychiatric warnings | 
| Flonase | fluticasone (intranasal) | corticosteroid | allergic rhinitis | epistaxis | 
| Claritin | loratadine | 2nd‑gen antihistamine | allergy | minimal sedation | 
| Zyrtec | cetirizine | 2nd‑gen antihistamine | allergy | drowsiness (some) | 
Anti‑infectives
| Brand | Generic | Class | Primary use | Key red‑flag | 
| Amoxil | amoxicillin | penicillin | bacterial infections | rash/allergy | 
| Augmentin | amoxicillin/clavulanate | penicillin + β-lactamase inhibitor | bacterial infections | GI upset | 
| Keflex | cephalexin | 1st‑gen cephalosporin | bacterial infections | cross‑allergy (PCN) | 
| Omnicef | cefdinir | 3rd‑gen cephalosporin | bacterial infections | diarrhea | 
| Zithromax | azithromycin | macrolide | bacterial infections | QT prolongation | 
| Levaquin | levofloxacin | fluoroquinolone | bacterial infections | tendon rupture | 
| Cipro | ciprofloxacin | fluoroquinolone | bacterial infections | tendon rupture | 
| Vibramycin | doxycycline | tetracycline | bacterial infections/ acne | photosensitivity; separate from cations | 
| Bactrim / Septra | sulfamethoxazole/trimethoprim | sulfonamide | bacterial infections | rash, hyperkalemia | 
| Flagyl | metronidazole | nitroimidazole | bacterial infections | Avoid alcohol (disulfiram‑like) | 
| Macrobid | nitrofurantoin | urinary antiseptic | UTI | rare pulmonary/hepatic toxicity | 
| Diflucan | fluconazole | azole antifungal | Fungal infections | hepatotoxicity | 
| Valtrex | valacyclovir | antiviral | Herpes / Shingles | renal dosing | 
GI & other high‑yield
| Brand | Generic | Class | Primary use | Key red‑flag | 
| Prilosec | omeprazole | PPI | GERD | low Mg, fracture risk (long‑term) | 
| Protonix | pantoprazole | PPI | GERD | low Mg | 
| Pepcid | famotidine | H2 blocker | GERD | confusion (elderly) | 
| Zofran | ondansetron | 5‑HT3 antagonist | N/V | QT prolongation | 
| Reglan | metoclopramide | prokinetic | gastroparesis | EPS/tardive dyskinesia | 
| Colace | docusate | stool softener | constipation | cramping | 
| MiraLAX | polyethylene glycol | osmotic laxative | constipation | diarrhea | 
| Fosamax | alendronate | bisphosphonate | osteoporosis | esophagitis (empty stomach; upright) | 
| Flomax | tamsulosin | α1‑blocker | BPH | orthostasis | 
| Proscar | finasteride | 5‑α‑reductase inhibitor | BPH | teratogenic; avoid handling in pregnancy | 
| Ditropan | oxybutynin | antimuscarinic | OAB | dry mouth, constipation | 
| (no brand) | prednisone | corticosteroid | inflammation | hyperglycemia, infection risk | 
| Medrol | methylprednisolone | corticosteroid | inflammation | class effects | 
| Neurontin | gabapentin | anticonvulsant | neuropathic pain | dizziness/sedation | 
| Tylenol | acetaminophen | analgesic | pain/fever | hepatotoxicity (dose limits) | 
| Motrin / Advil | ibuprofen | NSAID | pain | GI bleed, renal risk | 
| Naprosyn / Aleve | naproxen | NSAID | pain | GI bleed, renal risk | 
| Norco / Vicodin | hydrocodone/acetaminophen | opioid combo | pain | sedation, constipation | 
| Percocet | oxycodone/acetaminophen | opioid combo | pain | sedation, constipation | 
| Narcan | naloxone | opioid antagonist | overdose | acute withdrawal | 
Note: Some legacy brand names are no longer marketed but still appear in study resources: know the mapping.
Class‑by‑class overview: what each group treats (+ gotchas)
- ACE inhibitors (‑pril): HTN/HF/nephroprotection; avoid in pregnancy; monitor K⁺.
- ARBs (‑sartan): HTN/HF; avoid in pregnancy; monitor K⁺.
- DHP CCBs (‑dipine): HTN; edema; possible gingival hyperplasia.
- β‑blockers (‑olol): HTN/angina/AF/HF; bradycardia; avoid abrupt stop.
- Thiazides: HTN; hypokalemia; photosensitivity.
- Loops: edema/HF; hypokalemia; ototoxicity (high dose/rapid IV).
- Statins (‑statin): dyslipidemia; myopathy; avoid in pregnancy.
- Sulfonylureas: T2DM; hypoglycemia; weight gain.
- SGLT2 inhibitors (‑gliflozin): T2DM/HF; genital infections; volume depletion.
- GLP‑1 RAs: T2DM/weight; GI effects; class boxed warning for thyroid C‑cell tumors.
- SSRIs/SNRIs: depression/anxiety; sexual dysfunction (SSRIs), ↑BP (SNRIs).
- Atypical antipsychotics: schizophrenia/bipolar; metabolic effects.
- Opioids: sedation, constipation, respiratory depression; combine with naloxone education.
- Macrolides: QT risk; CYP interactions.
- Fluoroquinolones: tendinopathy, QT risk; reserve when appropriate.
- Tetracyclines: photosensitivity; separate from cations.
- PPIs: infection/nutrient effects with long-term use.
High-risk side effects & interactions to know cold
- Anticoagulants/antiplatelets (warfarin, DOACs, clopidogrel) → bleeding risks
- Insulins & sulfonylureas → hypoglycemia
- ACEi/ARB/K‑sparing diuretics → hyperkalemia
- Fluoroquinolones, macrolides, ondansetron → QT prolongation.
- Metronidazole + alcohol → disulfiram‑like reaction
- Statins + strong CYP inhibitors → myopathy risk.
- Benzodiazepines + opioids → additive respiratory depression.
Mini Top 200 Drugs self-test: 10 quick questions
Loading question…
FAQs
What is the best way to memorize the Top 200 drugs?
Break the list into classes, memorize suffixes, and drill brand↔generic with spaced‑repetition flashcards. Tie one primary use and one red‑flag effect to each drug. Practice daily in 10–15 minute sets.
Do I need to memorize both brand and generic names?
Yes. Brand↔generic matching is frequently tested and speeds up class-based questions that reference only one of the two.
How many drugs are on the PTCE?
There isn’t an official list; “Top 200” is a study convention. Expect many medication questions—Medications are 40% through 2025 and 35% beginning January 2026. See PTCB’s outline and the 2026 outline.
Which suffixes should I know first?
Start with –pril (ACEi), –sartan (ARB), –olol (β‑blocker), –dipine (DHP CCB), –statin (statins), –prazole (PPIs), –gliflozin (SGLT2), –gliptin (DPP‑4), –cillin (penicillins), –floxacin (FQs).
Are posters helpful study aids?
Yes. The University of Arizona’s Njardarson Lab publishes free Top 200 posters (by sales or prescriptions). They’re great for context alongside your flashcards.
Resources
- PTCE Study Guide (Pharmacy Tech Scholar℠) — complete exam blueprint, tips, and practice.
- PTCB: PTCE Content Outline (current) and Effective Jan 2026.
- DailyMed and FDALabel — label‑verified indications and safety.
- Njardarson Top 200 Posters (University of Arizona) — annual context.
Abbreviations Used in this Guide
| Abbreviation | Meaning | 
|---|---|
| 5‑HT3 | 5‑hydroxytryptamine (serotonin) type‑3 receptor | 
| ACEi | Angiotensin‑converting enzyme inhibitor | 
| AF | Atrial fibrillation | 
| ARB | Angiotensin II receptor blocker | 
| ASCVD | Atherosclerotic cardiovascular disease | 
| BPH | Benign prostatic hyperplasia | 
| BP | Blood pressure | 
| CCB | Calcium channel blocker | 
| C. difficile | Clostridioides difficile (bacterium that can cause severe diarrhea) | 
| COPD | Chronic obstructive pulmonary disease | 
| CV | Cardiovascular | 
| CYP | Cytochrome P450 drug‑metabolizing enzyme system | 
| DHP | Dihydropyridine (subclass of CCBs) | 
| DOAC | Direct oral anticoagulant | 
| DPP‑4 | Dipeptidyl peptidase‑4 | 
| EPS | Extrapyramidal symptoms (movement‑related adverse effects) | 
| GERD | Gastroesophageal reflux disease | 
| GI | Gastrointestinal | 
| GLP‑1 RA | Glucagon‑like peptide‑1 receptor agonist | 
| HF | Heart failure | 
| H2 (blocker) | Histamine‑2 receptor antagonist | 
| HTN | Hypertension | 
| ICS | Inhaled corticosteroid | 
| ICS/LABA | Combination of inhaled corticosteroid + long‑acting beta agonist | 
| INR | International Normalized Ratio (measure of blood coagulation) | 
| K+ | Potassium (positively charged ion) | 
| K‑sparing | Potassium‑sparing (typically refers to diuretics) | 
| LABA | Long‑acting beta agonist | 
| LAMA | Long‑acting muscarinic antagonist | 
| Mg | Magnesium | 
| NDRI | Norepinephrine–dopamine reuptake inhibitor | 
| N/V | Nausea and vomiting | 
| NSAID | Nonsteroidal anti‑inflammatory drug | 
| OAB | Overactive bladder | 
| PCN | Penicillin | 
| PPI | Proton pump inhibitor | 
| PTCE | Pharmacy Technician Certification Exam | 
| PTCB | Pharmacy Technician Certification Board | 
| QT (prolongation) | Heart’s QT interval (abnormal prolongation increases arrhythmia risk) | 
| RA | Receptor agonist (as in GLP‑1 RA) | 
| SABA | Short‑acting beta agonist | 
| SGLT2 | Sodium‑glucose cotransporter 2 | 
| SJS/TEN | Stevens‑Johnson syndrome / toxic epidermal necrolysis | 
| SNRI | Serotonin–norepinephrine reuptake inhibitor | 
| SR | Sustained‑release (dosage form) | 
| SSRI | Selective serotonin reuptake inhibitor | 
| T1DM | Type 1 diabetes mellitus | 
| T2DM | Type 2 diabetes mellitus | 
| TCA | Tricyclic antidepressant | 
| U.S. | United States | 
| UTI | Urinary tract infection | 
| VKA | Vitamin K antagonist | 
| VTE | Venous thromboembolism | 
| VZV | Varicella‑zoster virus | 
| HSV | Herpes simplex virus | 
| XR | Extended‑release (dosage form) | 
| XL | Extended‑release (dosage form) | 
| β‑blocker | Beta‑adrenergic receptor blocker | 
| β1 | Beta‑1 (cardioselective) subtype | 
| α1 | Alpha‑1 adrenergic receptor | 
Symbols Used
- ↑ = increase; ↓ = decrease
- / = combination (e.g., AF/VTE; ICS/LABA)
- → = “leads to” or “results in” (used in side‑effect callouts)